LEADER 00834nam0-2200301 --450 001 9910584695203321 005 20220803162130.0 010 $b(errato)$z88-430-2154-0 010 $a978-88-430-2154-3$b5.^rist.^2009 020 $aIT$b2003-2239 100 $a20220803d2002----kmuy0itay5050 ba 101 0 $aita 102 $aIT 105 $a 001yy 200 1 $aChe cos'è la pedagogia sperimentale$fRita Gatti 210 $aRoma$cCarocci$d2002 215 $a111 p.$d20 cm 225 1 $aBussole$v42 610 0 $aPedagogia sperimentale 676 $a370.72$v21 700 1$aGatti,$bRita$0188377 801 0$aIT$bUNINA$gREICAT$2UNIMARC 901 $aBK 912 $a9910584695203321 952 $a370.72 GAT 1$b2021/3052$fFLFBC 959 $aFLFBC 996 $aChe cos'è la pedagogia sperimentale$9281819 997 $aUNINA LEADER 00983nam a2200277 i 4500 001 991001488809707536 008 s us 000 0 eng d 020 $a0199276129 035 $ab13380333-39ule_inst 040 $aDip. SSC$bita 082 0 $a322.3 245 10$aPolicy-making in the European Union /$cedited by Helen Wallace, William Wallace and Mark A. Pollack 250 $a5. ed. 260 $aNew York :$bOxford University Press,$c2005 300 $aXXXIX, 570 p. ;$c25 cm 440 4$aThe new European Union 650 4$aUnione europea 700 1 $aWallace, Helen 700 1 $aWallace, William 700 1 $aPollack, Mark A. 907 $a.b13380333$b21-09-06$c20-02-06 912 $a991001488809707536 945 $aLE021 SOC25A3$g1$i2021000119705$lle021$nSchiavone$o-$pE0.00$q-$rl$s- $t0$u0$v0$w0$x0$y.i14195100$z20-02-06 996 $aPolicy-making in the European Union$91090427 997 $aUNISALENTO 998 $ale021$b20-02-06$cm$d- $e-$feng$gus $h0$i0 LEADER 05800nam 2200841Ia 450 001 9910816078003321 005 20200520144314.0 010 $a9786613622402 010 $a9781280592577 010 $a1280592575 010 $a9781118180761 010 $a1118180763 010 $a9781118180778 010 $a1118180771 010 $a9781118180747 010 $a1118180747 035 $a(CKB)2670000000177367 035 $a(EBL)822074 035 $a(SSID)ssj0000631663 035 $a(PQKBManifestationID)11415164 035 $a(PQKBTitleCode)TC0000631663 035 $a(PQKBWorkID)10599442 035 $a(PQKB)10606429 035 $a(Au-PeEL)EBL822074 035 $a(CaPaEBR)ebr10560514 035 $a(CaONFJC)MIL362240 035 $a(OCoLC)795631979 035 $a(MiAaPQ)EBC822074 035 $a(Perlego)1003437 035 $a(EXLCZ)992670000000177367 100 $a20110720d2012 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aADME-enabling technologies for drug design and development /$fedited by Donglu Zhang, Sekhar Surapaneni 205 $a1st ed. 210 $aHoboken, N.J. $cWiley$dc2012 215 $a1 online resource (623 p.) 300 $aDescription based upon print version of record. 311 08$a9780470542781 311 08$a0470542780 320 $aIncludes bibliographical references and index. 327 $aADME-Enabling Technologies in Drug Design and Development; CONTENTS; FOREWORD; PREFACE; CONTRIBUTORS; PART A: ADME: OVERVIEW AND CURRENT TOPICS; 1: REGULATORY DRUG DISPOSITION AND NDA PACKAGE INCLUDING MIST; 1.1 INTRODUCTION; 1.2 NONCLINICAL OVERVIEW; 1.3 PK; 1.4 ABSORPTION; 1.5 DISTRIBUTION; 1.5.1 Plasma Protein Binding; 1.5.2 Tissue Distribution; 1.5.3 Lacteal and Placental Distribution Studies; 1.6 METABOLISM; 1.6.1 In vitro Metabolism Studies; 1.6.2 Drug-Drug Interaction Studies; 1.6.3 In vivo Metabolism (ADME) Studies; 1.7 EXCRETION; 1.8 IMPACT OF METABOLISM INFORMATION ON LABELING 327 $a1.9 CONCLUSIONSREFERENCES; 2: OPTIMAL ADME PROPERTIES FOR CLINICAL CANDIDATE AND INVESTIGATIONAL NEW DRUG (IND) PACKAGE; 2.1 INTRODUCTION; 2.2 NCE AND INVESTIGATIONAL NEW DRUG (IND) PACKAGE; 2.3 ADME OPTIMIZATION; 2.3.1 Absorption; 2.3.2 Metabolism; 2.3.3 PK; 2.4 ADME OPTIMIZATION FOR CNS DRUGS; 2.5 SUMMARY; REFERENCES; 3: DRUG TRANSPORTERS IN DRUG INTERACTIONS AND DISPOSITION; 3.1 INTRODUCTION; 3.2 ABC TRANSPORTERS; 3.2.1 Pgp (MDR1, ABCB1); 3.2.2 BCRP (ABCG2); 3.2.3 MRP2 (ABCC2); 3.3 SLC TRANSPORTERS; 3.3.1 OCT1 (SLC22A1) and OCT2 (SLC22A2); 3.3.2 MATE1 (SLC47A1) and MATE2K (SLC47A2) 327 $a3.3.3 OAT1 (SLC22A6) and OAT3 (SLC22A8)3.3.4 OATP1B1 (SLCO1B1, SLC21A6), OATP1B3 (SLCO1B3, SLC21A8), and OATP2B1 (SLCO2B1, SLC21A9); 3.4 IN VITRO ASSAYS IN DRUG DEVELOPMENT; 3.4.1 Considerations for Assessing Candidate Drugs as Inhibitors; 3.4.2 Considerations for Assessing Candidate Drugs as Substrates; 3.4.3 Assay Systems; 3.5 CONCLUSIONS AND PERSPECTIVES; REFERENCES; 4: PHARMACOLOGICAL AND TOXICOLOGICAL ACTIVITY OF DRUG METABOLITES; 4.1 INTRODUCTION; 4.2 ASSESSMENT OF POTENTIAL FOR ACTIVE METABOLITES; 4.2.1 Detection of Active Metabolites during Drug Discovery 327 $a4.2.2 Methods for Assessing and Evaluating the Biological Activity of Metabolite Mixtures4.2.3 Methods for Generation of Metabolites; 4.3 ASSESSMENT OF THE POTENTIAL TOXICOLOGY OF METABOLITES; 4.3.1 Methods to Study the Formation of Reactive Metabolites; 4.3.2 Reactive Metabolite Studies: In vitro; 4.3.3 Reactive Metabolite Studies: In vivo; 4.3.4 Reactive Metabolite Data Interpretation; 4.3.5 Metabolite Contribution to Off-Target Toxicities; 4.4 SAFETY TESTING OF DRUG METABOLITES; 4.5 SUMMARY; REFERENCES 327 $a5: IMPROVING THE PHARMACEUTICAL PROPERTIES OF BIOLOGICS IN DRUG DISCOVERY: UNIQUE CHALLENGES AND ENABLING SOLUTIONS5.1 INTRODUCTION; 5.2 PHARMACOKINETICS; 5.3 METABOLISM AND DISPOSITION; 5.4 IMMUNOGENICITY; 5.5 TOXICITY AND PRECLINICAL ASSESSMENT; 5.6 COMPARABILITY; 5.7 CONCLUSIONS; REFERENCES; 6: CLINICAL DOSE ESTIMATION USING PHARMACOKINETIC/PHARMACODYNAMIC MODELING AND SIMULATION; 6.1 INTRODUCTION; 6.2 BIOMARKERS IN PK AND PD; 6.2.1 PK; 6.2.2 PD; 6.2.3 Biomarkers; 6.3 MODEL-BASED CLINICAL DRUG DEVELOPMENT; 6.3.1 Modeling; 6.3.2 Simulation; 6.3.3 Population Modeling 327 $a6.3.4 Quantitative Pharmacology (QP) and Pharmacometrics 330 $a A comprehensive guide to cutting-edge tools in ADME research The last decade has seen tremendous progress in the development of analytical techniques such as mass spectrometry and molecular biology tools, resulting in important advances in drug discovery, particularly in the area of absorption, distribution, metabolism, and excretion (ADME). ADME-Enabling Technologies in Drug Design and Development focuses on the current state of the art in the field, presenting a comprehensive review of the latest tools for generating ADME data in drug discovery. It examines the broadest possible rang 606 $aDrugs$xDesign 606 $aDrug development 606 $aDrugs$xMetabolism 606 $aPharmaceutical chemistry 606 $aPharmacokinetics 606 $aPharmaceutical technology 615 0$aDrugs$xDesign. 615 0$aDrug development. 615 0$aDrugs$xMetabolism. 615 0$aPharmaceutical chemistry. 615 0$aPharmacokinetics. 615 0$aPharmaceutical technology. 676 $a615.1/9 701 $aZhang$b Donglu$01621376 701 $aSurapaneni$b Sekhar$01720344 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910816078003321 996 $aADME-enabling technologies for drug design and development$94118918 997 $aUNINA